Результаты поиска

Exploring the Complexity and Promise of Tumor Immunotherapy in Drug Development.

Cancer represents a significant threat to human health, and traditional chemotherapy or cytotoxic therapy is no longer the sole or preferred approach for managing malignant tumors. With advanced research into the immunogenicity of tumor cells and the growing elderly population, tumor immunotherapy has emerged as a prominent therapeutic option. Its significance in treating elderly cancer patients is increasingly recognized. In this study, we review the conceptual classifications and benefits of immunotherapy, and discuss recent developments in new drugs and clinical progress in cancer treatment

Совпадение в полном тексте источника
… Qi Y. Ann D.K. Starr R. IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype Cancer Immunol. Res. 2019 7 759 772 10.1158/2326-6066.Cir-18-0466 30890531 PMC6687561 89. Finn O.J. …

Bispecific Antibodies for the Management of Relapsed/Refractory Multiple Myeloma.

Bispecific antibodies (BsAbs) are artificially engineered antibodies that can bind simultaneously to the CD3 subunit within the T-cell receptor complex and an antigen on tumor cells, leading to T-cell activation and tumor cell killing. BsAbs against BCMA or GPRC5D have shown impressive clinical activity in heavily pretreated patients with relapsed/refractory multiple myeloma (RRMM), with some agents having already received regulatory approval after the third (by the European Medicines Agency, EMA) or fourth (by the Food and Drug Administration, FDA) line of therapy; the results of early-phase

Совпадение в полном тексте источника
… Usmani S.Z., Karlin L., Benboubker L., Nahi H., San-Miguel J., Trancucci D., Qi K., Stephenson T., Perales-Puchalt A., Chastain K., et al. …

Agents contributing to secondary immunodeficiency development in patients with multiple myeloma, chronic lymphocytic leukemia and non-Hodgkin lymphoma: A systematic literature review.

IntroductionPatients with hematological malignancies (HMs), like chronic lymphocytic leukemia (CLL), multiple myeloma (MM), and non-Hodgkin lymphoma (NHL), have a high risk of secondary immunodeficiency (SID), SID-related infections, and mortality. Here, we report the results of a systematic literature review on the potential association of various cancer regimens with infection rates, neutropenia, lymphocytopenia, or hypogammaglobulinemia, indicative of SID.MethodsA systematic literature search was performed in 03/2022 using PubMed to search for clinical trials that mentioned in the title and

Совпадение в полном тексте источника
… Lancet ( 2020 ) 396 ( 10245 ): 186–97 . doi: 10.1016/S0140-6736(20)30734-0 32682484 98 Dimopoulos M Siegel DS Lonial S Qi J Hajek R Facon T . Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): A multicentre, randomised, double-blind study . …

Toxicity Profile of Chimeric Antigen Receptor T-Cell and Bispecific Antibody Therapies in Multiple Myeloma: Pathogenesis, Prevention and Management.

Multiple myeloma is the second-most common hematologic malignancy in adults worldwide. Despite ongoing advancement in therapeutic modalities, it remains an incurable disease with a 5-year survival rate of approximately 50%. The recent development and introduction of anti-BCMA immunotherapies into clinical practice, including chimeric antigen receptor T-cell (CAR-T) therapies and bispecific antibodies, has radically shifted the treatment paradigm. However, despite the promising potential of these therapies for broader application, frequent and significant adverse effects have been reported, bot

Совпадение в полном тексте источника
… Xia J., Li H., Yan Z., Zhou D., Wang Y., Qi Y., Cao J., Li D., Cheng H., Sang W., et al. Anti-G Protein-Coupled Receptor, Class C Group 5 Member D Chimeric Antigen Receptor T Cells in Patients With Relapsed or Refractory Multiple Myeloma: A Single-Arm, Phase II Trial. J. Clin. …

Exploiting Nanomedicine for Cancer Polychemotherapy: Recent Advances and Clinical Applications.

The most important limitations of chemotherapeutic agents are severe side effects and the development of multi-drug resistance. Recently, the clinical successes achieved with immunotherapy have revolutionized the treatment of several advanced-stage malignancies, but most patients do not respond and many of them develop immune-related adverse events. Loading synergistic combinations of different anti-tumor drugs in nanocarriers may enhance their efficacy and reduce life-threatening toxicities. Thereafter, nanomedicines may synergize with pharmacological, immunological, and physical combined tre

Совпадение в полном тексте источника
… Qi R. Zhou Z. Deng Z. Shi J. Qin T. Zhao S. Qian Y. Shen J. Simultaneous Delivery of Gene and Chemotherapeutics via Copolymeric Micellar Nanoparticles to Overcome Multiple Drug Resistance to Promote Synergistic Tumor Suppression J. Biomater. …

Current Advancement of Immunomodulatory Drugs as Potential Pharmacotherapies for Autoimmunity Based Neurological Diseases.

Dramatic advancement has been made in recent decades to understand the basis of autoimmunity-mediated neurological diseases. These diseases create a strong influence on the central nervous system (CNS) and the peripheral nervous system (PNS), leading to various clinical manifestations and numerous symptoms. Multiple sclerosis (MS) is the most prevalent autoimmune neurological disease while NMO spectrum disorder (NMOSD) is less common. Furthermore, evidence supports the presence of autoimmune mechanisms contributing to the pathogenesis of amyotrophic lateral sclerosis (ALS), which is a neurodeg

Совпадение в полном тексте источника
… Filichia E., Hoffer B., Qi X., Luo Y. Inhibition of Drp1 mitochondrial translocation provides neural protection in dopaminergic system in a Parkinson’s disease model induced by MPTP. Sci. Rep. 2016;6:32656. doi: 10.1038/srep32656. 141. White C.M., Ji S., Cai H., Maudsley S., Martin B. …

Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy.

Cancer is one of the primary causes of worldwide human deaths. Most cancer patients receive chemotherapy and radiotherapy, but these treatments are usually only partially efficacious and lead to a variety of serious side effects. Therefore, it is necessary to develop new therapeutic strategies. The emergence of nanotechnology has had a profound impact on general clinical treatment. The application of nanotechnology has facilitated the development of nano-drug delivery systems (NDDSs) that are highly tumor selective and allow for the slow release of active anticancer drugs. In recent years, veh

Совпадение в полном тексте источника
… Chen J., Qi J., Chen C., Chen J., Liu L., Gao R., Zhang T., Song L., Ding D., Zhang P. Tocilizumab–Conjugated Polymer Nanoparticles for NIR-II Photoacoustic-Imaging-Guided Therapy of Rheumatoid Arthritis. Adv. Mater. 2020;32:2003399. doi: 10.1002/adma.202003399. 128. …

Clinical Insights Into Novel Immune Checkpoint Inhibitors.

The success of immune checkpoint inhibitors (ICIs), notably anti-cytotoxic T lymphocyte associated antigen-4 (CTLA-4) as well as inhibitors of CTLA-4, programmed death 1 (PD-1), and programmed death ligand-1 (PD-L1), has revolutionized treatment options for solid tumors. However, the lack of response to treatment, in terms of de novo or acquired resistance, and immune related adverse events (IRAE) remain as hurdles. One mechanisms to overcome the limitations of ICIs is to target other immune checkpoints associated with tumor microenvironment. Immune checkpoints such as lymphocyte activation ge

Protective Effects of Flavonoids Against Mitochondriopathies and Associated Pathologies: Focus on the Predictive Approach and Personalized Prevention.

Multi-factorial mitochondrial damage exhibits a "vicious circle" that leads to a progression of mitochondrial dysfunction and multi-organ adverse effects. Mitochondrial impairments (mitochondriopathies) are associated with severe pathologies including but not restricted to cancers, cardiovascular diseases, and neurodegeneration. However, the type and level of cascading pathologies are highly individual. Consequently, patient stratification, risk assessment, and mitigating measures are instrumental for cost-effective individualized protection. Therefore, the paradigm shift from reactive to pred

Совпадение в полном тексте источника
… Qi X. Yogalingam G. Ferreira J.C.B. Mochly-Rosen D. Regulation of mitochondrial processes: A target for heart failure Drug Discov. Today: Dis. Mech. 2010 7 e95 e102 10.1016/j.ddmec.2010.07.002 21278905 PMC3026286 66. Dolinsky V.W. Cole L.K. Sparagna G.C. Hatch G.M. …

The Roadmap of RANKL/RANK Pathway in Cancer.

The receptor activator of the nuclear factor-κB ligand (RANKL)/RANK signaling pathway was identified in the late 1990s and is the key mediator of bone remodeling. Targeting RANKL with the antibody denosumab is part of the standard of care for bone loss diseases, including bone metastases (BM). Over the last decade, evidence has implicated RANKL/RANK pathway in hormone and HER2-driven breast carcinogenesis and in the acquisition of molecular and phenotypic traits associated with breast cancer (BCa) aggressiveness and poor prognosis. This marked a new era in the research of the therapeutic use o

Совпадение в полном тексте источника
… Zhang J., Dai J., Qi Y., Lin D.L., Smith P., Strayhorn C., Mizokami A., Fu Z., Westman J., Keller E.T. Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. J. Clin. Investig. 2001;107:1235–1244. doi: 10.1172/JCI11685. 49. …

The DNA methylation landscape of multiple myeloma shows extensive inter- and intrapatient heterogeneity that fuels transcriptomic variability.

BackgroundCancer evolution depends on epigenetic and genetic diversity. Historically, in multiple myeloma (MM), subclonal diversity and tumor evolution have been investigated mostly from a genetic perspective.MethodsHere, we performed an analysis of 42 MM samples from 21 patients by using enhanced reduced representation bisulfite sequencing (eRRBS). We combined several metrics of epigenetic heterogeneity to analyze DNA methylation heterogeneity in MM patients.ResultsWe show that MM is characterized by the continuous accumulation of stochastic methylation at the promoters of development-related

Совпадение в полном тексте источника
… Reece DE Chung KC Tiedemann RE Xbp1s-negative tumor B cells and pre-plasmablasts mediate therapeutic proteasome inhibitor resistance in multiple myeloma Cancer Cell 2013 24 3 289 304 10.1016/j.ccr.2013.08.009 24029229 PMC4118579 2 Zhang X-D Baladandayuthapani V Lin H Mulligan G Li B Esseltine D-LW Qi …

Gut-Bone Axis: A Non-Negligible Contributor to Periodontitis.

Periodontitis is a polymicrobial infectious disease characterized by alveolar bone loss. Systemic diseases or local infections, such as diabetes, postmenopausal osteoporosis, obesity, and inflammatory bowel disease, promote the development and progression of periodontitis. Accumulating evidences have revealed the pivotal effects of gut microbiota on bone health via gut-alveolar-bone axis. Gut pathogens or metabolites may translocate to distant alveolar bone via circulation and regulate bone homeostasis. In addition, gut pathogens can induce aberrant gut immune responses and subsequent homing o

Совпадение в полном тексте источника
… Commun. 355 (4), 913–918. doi: 10.1016/j.bbrc.2007.02.057 Cheng S., Qi X., Ma M., Zhang L., Cheng B., Liang C., et al. (2020). Assessing the Relationship Between Gut Microbiota and Bone Mineral Density. Front. Genet. 11, 6. doi: 10.3389/fgene.2020.00006 Cho Y. E., Kim D. …

Developments in continuous therapy and maintenance treatment approaches for patients with newly diagnosed multiple myeloma.

The evolving paradigm of continuous therapy and maintenance treatment approaches in multiple myeloma (MM) offers prolonged disease control and improved outcomes compared to traditional fixed-duration approaches. Potential benefits of long-term strategies include sustained control of disease symptoms, as well as continued cytoreduction and clonal control, leading to unmeasurable residual disease and the possibility of transforming MM into a chronic or functionally curable condition. "Continuous therapy" commonly refers to administering a doublet or triplet regimen until disease progression, whe

Совпадение в полном тексте источника
… , Lucio Paulo, Nagy Zsolt, Kaplan Polina, Pour Ludek, Cook Mark, Grosicki Sebastian, Crepaldi Andre H, Liberati Anna Marina, Campbell Philip, Shelekhova Tatiana, Yoon Sung-Soo, Iosava Genadi, Fujisaki Tomoaki, Garg Mamta, Chiu Christopher, Wang Jianping, Kudva Anupa, Kobos Rachel, Wroblewski Susan, Qi …

Preclinical and Virtual Models of Mucosal Melanoma: Bridging Translational Gaps in a Rare and Lethal Cancer.

Mucosal melanoma (MM) is a rare and lethal subtype of melanoma, disproportionately affecting Asian populations and exhibiting distinct clinicopathological and genetic features compared to cutaneous melanoma (CM). Often diagnosed at advanced stages, MM shows poor responses to conventional therapies, and no standardized treatment regimen currently exists. Progress in preclinical modeling, including cell lines, patient-derived xenografts (PDXs), organoids (PDOs), and comparative animal models-has provided valuable tools for studying MM pathogenesis and therapeutic resistance. Yet these models rem

Совпадение в полном тексте источника
… Mao, L. , Qi Z., Zhang L., Guo J., and Si L.. 2021. “Immunotherapy in Acral and Mucosal Melanoma: Current Status and Future Directions.” Frontiers in Immunology 12: 680407. 10.3389/fimmu.2021.680407. Mao, L. L. , Si L., Kong Y., et al. 2016. …

The Potential of Chronotherapy and Nanotherapy-Based Strategies for Glioblastoma Treatment.

Glioblastoma is the most common and aggressive brain tumour in adults, and despite ongoing efforts, effective treatment remains limited. Standard therapies often face challenges because of the tumour's specific biology, its aggressive nature, and the presence of certain physiological barriers in the brain that impede chemotherapeutics from reaching their target. Emerging research in circadian biology highlights the role of the internal circadian clock in tumour progression and treatment response. Evidence suggests that aligning therapy to patients' chronotypes could potentially improve treatme

Exosomes-loaded with traditional Chinese medicine constituents: a novel therapeutic avenue for aplastic anemia.

Aplastic anemia (AA) is a life-threatening blood disorder characterized by bone marrow failure and pancytopenia. Treatments such as immunosuppressive therapy (IST) and allogeneic hematopoietic stem cell transplantation (allo-HSCT) have limitations, including poor long-term remission and donor shortages. Exosomes, nanosized extracellular vesicles, are promising drug delivery systems (DDS) due to their biocompatibility, targeted delivery, and capacity to penetrate biological barriers. Traditional Chinese medicine (TCM) regulates hematopoiesis and immunity but faces challenges with delivery. This

Совпадение в полном тексте источника
… Shao Y, Qi W, Zhang X, Ran N, Liu C, Fu R, et al. Plasma metabolomic and intestinal microbial analyses of patients with severe aplastic anemia. Front Cell Dev Biol. 2021;9:669887. 18. Sweeney R, Esmail F, Mirza KM, Nand S. …

Ocular toxicity associated with antibody-drug conjugates in cancer therapy: a comprehensive review.

Ocular toxicity from anti-cancer drugs is frequently overlooked, largely because it is non-life-threatening, whereas clinical priorities often center on adverse events that pose immediate risks to survival. Antibody-drug conjugates (ADCs) have emerged as an important therapeutic modality in oncology, offering potent cytotoxicity against tumor cells through the targeted delivery of payloads. However, this potency also introduces a spectrum of toxicities, among which ocular toxicity has gained increasing attention. ADC-induced ocular toxicity can impair visual function and significantly compromi

Совпадение в полном тексте источника
… Ma P, Tian H, Shi Q, Liu R, Zhang Y, Qi X, et al. High risks adverse events associated with trastuzumab emtansine and trastuzumab deruxtecan for the treatment of HER2-positive/mutated Malignancies: a pharmacovigilance study based on the FAERS database. …

Evaluating patient-reported outcomes in randomized controlled trials of targeted therapy and/or immunotherapy for liver cancer: a scoping review.

ObjectiveTo assess the reporting characteristics and quality of patient-reported outcomes (PROs) in randomized controlled trials (RCTs) of targeted therapy and/or immunotherapy for liver cancer.MethodsWe systematically searched six electronic databases for relevant RCTs published in English or Chinese from inception to April 17, 2025. The reporting quality of PROs was assessed using the CONSORT-PRO extension and the CONSORT 2010 guidelines.ResultsWe included 64 RCTs with 8,494 participants. Of these, 14 studies were confirmatory studies, 31 studies were exploratory studies and 19 studies were

Совпадение в полном тексте источника
… Cuixia Q, Xinfeng Z, Xufeng C, Qi L, Xiaoping C. The influence of autologous cytokine-induced killer cells combined with targeted therapy for liver cancer on the quality of life of elderly patients with liver cancer. …

IL-34 в неврологическом гомеостазисе и его многогранная роль в заболеваниях центральной нервной системы.

Interleukin-34 (IL-34), лиганд для рецептора макрофажных колоний (CSF1R), играет незаменимую роль в развитии и поддержании гомеостазиса центральной нервной системы (CNS). В настоящем обзоре систематически излагаются основные механизмы, с помощью которых ось сигнала IL-34/CSF1R регулирует развитие, колонизацию и функциональную дифференциацию иммунных клеток-резидентов, включая микроглию и макрофаги, связанные с границами (BAM). Она подчеркивает свою роль в критических физиологических процессах, таких, как синаптическое обрезка, созревание нервной цепи и поддержание целостности мозгового барьера

Совпадение в полном тексте источника
… Wang SY, Huang ZH, Duan R, Fu XX, Qi JW, Luo ZJ, et al. IL-34/TREM2 modulates microglia-mediated inflammation and provides neuroprotection in a mouse model of sporadic Alzheimer's disease. J Alzheimer’s Dis. (2025) 104:875–85. doi: 10.1177/13872877251320418 40. …

Integrating CRISPR/Cas technology with clinical trials: Principles, progress and challenges.

CRISPR represent a groundbreaking genome-editing technology that has revolutionized genetic modification. This innovative tool offers an unparalleled revolution in the future treatment of genetic disorders, neurological diseases, infectious diseases and cancer. Despite the rapid expansion of CRISPR applications, its clinical use in humans is still relatively limited, with only 69 active clinical trials and 6 completed studies reported so far. This review examined current clinical trials and their processes in addressing various diseases via the CRISPR/Cas system. While earlier literatures have

Совпадение в полном тексте источника
… TX Li, Yang Y.Y., Qi H.Z., Cui W.G., Zhang L., Fu X.X., et al. CRISPR/Cas9 therapeutics: progress and prospects. Signal Transduct Tar. 2023;8(1):36. 56. Liu Z., Shi M., Ren Y., Xu H., Weng S., Ning W., et al. Recent advances and applications of CRISPR-Cas9 in cancer immunotherapy. …